CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


hospitalized children with Covid19Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2163 SOC Wiki 1.00
drug1748 PTC299 Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Covid-19 Pediatric Observatory

In early December 2019, cases of pneumonia of unknown origin were reported in Wuhan, Hubei Province in the People's Republic of China. The disease spreads rapidly and the number of sick people is increasing. On January 3, 2020 a new virus of the coronavirus family is identified in samples of bronchoalveolar lavage fluid from a patient in Wuhan and subsequently confirmed as the cause of these pneumonias. On 7 January 2020, the World Health Organization (WHO) designated it as the new coronavirus 2019 (i.e. 2019-nCoV). On 11 February 2020, the WHO designated the disease associated with 2019-nCoV as coronavirus 2019 disease (COVID-19). On 12 March, WHO announced that the COVID-19 outbreak is a pandemic. As of March 24, 2020, more than 375,000 cases of COVID-19 had been diagnosed with more than 16,000 deaths attributed to this virus. (Ref WHO https://www.who.int/emergencies/diseases/novel-coronavirus-2019 ). In France, the number of cases rose from 105 cases at the end of February to 19615 confirmed cases on March 24. (Source Public Health France). Most of the cases are adults. However, children are not completely spared and serious cases have been described. These severe cases can be respiratory or extra-respiratory (e.g. myocarditis). We also know that pediatric and adult cases differ in terms of clinical, biological and imaging findings, particularly chest CT scans. However, the description of paediatric pictures, especially severe forms and the involvement of children suffering from co-morbidities, remains poorly reported. Finally, the risk factors for serious cases in children remain largely unknown. This observatory aim to describe the clinical phenotypes of hospitalized pediatric patients with Covid19 in France, according to age groups.

NCT04336956 COVID-19 Other: hospitalized children with Covid19

Primary Outcomes

Measure: Percentage of children with severe or critical form.

Time: Day 14

Secondary Outcomes

Measure: Percentage of children requiring intensive care support

Time: at admission

Measure: Percentage of children requiring intensive care support

Time: at day 14

Description: requiring intensive care support or not

Measure: Clinical symptoms of children

Time: at admission

Description: requiring intensive care support or not

Measure: Clinical symptoms of children

Time: day 14

Description: requiring intensive care support or not

Measure: Biological results of children

Time: at admission

Description: requiring intensive care support or not

Measure: Biological results of children

Time: day 14

Description: requiring intensive care support or not

Measure: CT chest of children

Time: at admission

Description: requiring intensive care support or not

Measure: Pulmonary echography

Time: Day 14

Measure: nasopharynx SARScov2 PCR

Time: at admission

Description: if available

Measure: nasopharynx sarscov2 load

Time: at day 7

Description: if available

Measure: nasopharynx multiplex PCR

Time: at admission

Description: days

Measure: number of hospital days

Time: up to 6 months


No related HPO nodes (Using clinical trials)